Multicentric Castleman’s Disease in a 21 Years Old Female : A Rare But Important Condition

Shahed Ahmad Chowdhury1*
Samira Taufiq Reshma2
Shanjana Islam3

1Department of Haematology
Chittagong Medical College
Chittagong, Bangladesh.
2Department of Haematology
Delta Health Care Ltd.
Chittagong, Bangladesh.
3Department of Pediatrics
University of Science & Technology Chittagong (USTC)
Chittagong, Bangladesh.

Abstract
Castleman’s disease, also known as angiofollicular lymph node hyperplasia, is a rare disease with two known expansion types, unicentric and multicentric, which plays a major role in determining therapy. The rare multicentric type is a lymphoproliferative disorder of unknown etiology and is characterized by various clinical manifestations and multiple organ involvement. This disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established till now. We here report a case of rare Multicentric Castleman’s Disease (MCD) in a 21 yrs old female. She presented with slowly enlarging lymph nodes in cervical and inguinal regions which lead to a histological diagnosis of this rare condition. Its clinical features, types, relevant investigations and current treatment modalities are discussed. Though rare, early suspicion of this condition may relieve the suffering, avoid unnecessary investigations, give opportunity to choose treatment options and can save lives.

Key words : Castleman’s disease; Lymph node; Hyperplasia.

INTRODUCTION
Castleman’s disease is an uncommon clinicopathological entity characterized by non-neoplastic lymph node hypertrophy and histologically characterized by angiofollicular lymph node hyperplasia. Castleman et al first described it in 1956 in a group of patients with localized benign lymphadenopathy1. There are two known expansion types of this disease, unicentric and multicentric, which plays a major role in determining therapy. Because of the rarity of this disease, epidemiological data like prevalence or incidence rates are not available. The average age of patients with unicentric Castleman’s disease is around 30 to 40 years of age. Patients with the multicentric form are usually around 50 to 60 years old. No dispositional age, race or sex seems to exist but the disease is widely associated with Human Herpes Virus 8 (HHV-8) and Human Immunodeficiency Virus (HIV) infection2. Most cases of Castleman’s Disease represent either the hyaline vascular variant (80–90% of cases) or the plasma cell variant (10–20%) a small percentage present with a mixed histologic appearance3. The hyaline-vascular histology accounts for most Unicentric Castleman’s Disease (UCD) cases and the plasma cell type characterizes most cases of Multicentric Castleman’s Disease (MCD). UCD is typically localized, associated with minimal symptoms, and treated with local therapy alone. However, MCD is a systemic disease that commonly occurs in the setting of HIV infection and is clinically characterized by diffuse lymphadenopathy, splenomegaly, anemia, and systemic inflammatory symptoms4. MCD is primarily treated with systemic therapies4.
CASE REPORT

A 21 years old female reported to a hospital with the complaints of fever for 1 year, which is swinging in nature, appearance and gradual enlargement of lumps under skin in cervical and inguinal regions and also with gradually distended abdomen for the same duration. She also had a history of associated anorexia, nausea, occasional vomiting and approximately 10kg wt loss over last 1 year. Her past medical and family history did not suggest any specific disease.

Physical examination revealed anaemia, bilateral pedal oedema, enlarged lymph nodes in cervical and inguinal regions, the largest one was located in the cervical region, approximately 3×2 cm in size. Per abdominal examination revealed splenomegaly about 1.5 cm from left costal margin. Liver was also enlarged and tender, about 2cm from right costal margin in mid clavicular line. Ascites was present with shifting dullness.

Blood count showed moderate anaemia (8g/dl) white blood cell count of 8×10⁹/L, Low normal platelet count (180×10⁹/L) with raised ESR (125 mm in 1st hour). Liver Function Test showed SGPT 62 U/L, SGOT 46 U/L and normal Prothrombin Time, but there was hypoalbuminaemia (S. Albumin 2.1 g/dl) and Hypergammaglobulinaemia (S. Globulin 6.3 gm/dl). CRP was 20 mg/dl. Screening for Anti HIV antibody was negative.

Ultrasonography of whole abdomen revealed hepatosplenomegaly, ascites, abdominal lymphadenopathy and hepatic Space Occupying Lesion (SOL).

FNAC of cervical lymph node showed non specific pattern of Castleman’s disease plasma cell type.

DISCUSSION

Castleman’s Disease is named after Benjamin Castleman, who first described the characteristic histopathological findings of angio-follicular lymph node hyperplasia in a localized lymph node region in 1954. Clinically the disease has 2 forms, First one is localized as first described by Castleman, which is more common and another one Multicentric Castleman’s Disease (MCD) with involvement of several sites, which was first described by Gaba et al. in 1972.

The histological subtypes of Castleman’s disease are as follows: Hyaline vascular variant (Unicentric in 72% of all cases) plasma cell variant (Unicentric in 18% and multicentric in 10% of all cases) mixed variant, and a plasmablastic variant of multicentric Castleman’s disease.

The localized form of the disease is mostly asymptomatic with a single site lymph node enlargement. The sites commonly involved are abdomen, peripheral lymph nodes and the mediastinum. It is often discovered incidentally during routine examination, chest X rays or due to discomfort secondary to local compression.

MCD is more common in elder male (Male/female ratio is 2.5:1 to 13:1). It is generally of the plasma cell type or mixed variant. MCD is a systemic disease with significant peripheral lymphadenopathy and hepatosplenomegaly, frequently with fever, night sweats, fatigue and weight loss. Abnormal laboratory findings include pancytopenia, abnormal function of liver and kidney, raised CRP, IL-6 and hypergammaglobulinaemia. The natural history of MCD is variable. Some patients may present with indolent disease and very slow progression over months to years, while others experience a relapsing-remitting course or an acute and fulminant disease that can be fatal within weeks; the latter courses are more common in patients with HIV associated MCD.

The pathogenesis of Castleman’s Disease is not fully understood, however, the central roles of Interleukin (IL-6) in UCD and both IL-6 and Human Herpes Virus (HHV-8) in MCD have been well described. Patients with Castleman’s Disease are at increased risk of developing lymphoma. Non-Hodgkin lymphoma has been reported in approximately 20% of patients with MCD, as well as in some patients with UCD.

Castleman’s disease is a pathological diagnosis made by excisional biopsy of the affected lymph node tissue. In cases of deeper or less accessible tissue, core needle biopsy is preferred to fine needle aspiration, because fine needle aspirations are insensitive for both UCD and MCD. Laboratory studies with blood counts and measurement of C-reactive protein, interleukin-6 and liver function should be done. In addition, HIV and HHV-8 testing should also be performed. In addition, there are some benign and malignant conditions, including lymphoma and thymoma, that may appear histologically similar to Castleman’s disease. Therefore, immunohistologic and immunologic gene rearrangement studies of the specimens can be useful in solidifying the diagnosis. Identifying an immunophenotypically varied population of B lymphocytes with polyclonal surface and cytoplasmic immunoglobulin markers helps to confirm the diagnosis of Castleman’s disease and differentiate it from lymphoma.

Localized Castleman’s Disease (UCD) usually has a good prognosis and requires surgical excision of the enlarged lymph node with no further treatment. Patients generally remain asymptomatic thereafter. MCD however tends to have a variable prognosis with no established treatment consensus. A variety of combination treatments have been tried with surgical excision, chemotherapy and steroids. In patients with associated Kaposi’s sarcoma, monthly combination chemotherapy (e.g. cyclophosphamide, vincristine, doxorubicin and prednisone) has been tried with limited success. Anti-IL6 antibodies have...
shown success with systemic symptoms, as have steroids. Most
treatment modalities involve immunosuppression, increasing
the chance of opportunistic infections. Recent suggestions of
treatment with antiviral drug, Gangciclovir or the anti-CD20 B
cell monoclonal antibody, Rituximab may markedly improve
outcome1.

The prognosis and outcome of the multicentric type depend on
many factors, like progression rate, associated infections and
co morbidities which can make the prognosis poor. There are
no clear data about how long the follow-up care should be
conducted2. Appropriate follow-up care should consider type,
progression rate, clinical course, response to treatment and
curability of the disease. It should be planned on the basis of
case merit.

CONCLUSION

Castleman’s disease is a rare disorder that remains a diagnostic
challenge. The aim of this case report is to revisit this very
uncommon condition and emphasize the importance of
histology to seal the diagnosis from other lymphoproliferative
conditions. Although surgical resection remains the standard
therapy for unicentric disease, the landscape for the man-
agement of multicentric disease continues to evolve. Rituximab
monotherapy is the current mainstay of therapy, and novel
agents targeting interleukin-6 represent exciting new additions
to the treatment armamentarium. Single-agent and combination
chemotherapies as well as antiviral therapy provide adjunctive
support, particularly in the setting of relapsed or refractory dis-
ease. The ongoing exploration of antiviral and novel strategies,
such as proteasome inhibition, is heralded. The management of
Castleman's disease also requires careful attention to potential
concomitant infections, malignancies and associated
syndromes.

DISCLOSURE

All the authors declared no competing interest.

REFERENCES